Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...

Capivasertib is taken as a twice-daily pill, in combination with the hormone therapy fulvestrant. The drug works by blocking ...

A gradual drip feed of investment into a diverse range of quality companies could be a smart approach, Nick Saunders writes.